Pharmacology II
Cynthia A. Faulkner, Samuel S. Faulkner
Addictions Counseling July 8, 2026 DOI: 10.1093/oso/9780197829752.003.0014 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The chapter distinguishes alternative psychoactive substances, which the authors say often fall outside traditional drug classifications, from therapeutic medications used in mental health and substance use disorder care. It argues that Prescription Drug Monitoring Programs are essential tools for improving outcomes and reducing harm. |
Abstract
Abstract: This chapter explores two distinct domains within psychopharmacology: alternative psychoactive substances and therapeutic medications. Alternative psychoactive substances, including synthetic cannabinoids, cathinones, hallucinogens, and opioids; herbal supplements; and inhalants, often fall outside traditional drug classifications. In contrast, therapeutic medications play a vital role in the clinical management of mental health and substance use disorders. These include medicines for co-occurring medical conditions, ADHD, sleep disturbances, and substance use disorders, as well as emerging practices like microdosing and Medication-Assisted Treatment (MAT). The Prescription Drug Monitoring Programs (PDMPs) are highlighted as essential tools for improving outcomes and reducing harm.